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Abstract
Background: Recent studies have reported that peripheral neuropathy (PN) is common in patients with Parkinson’s
disease (PD) and raised the possibility that levodopa neurotoxicity is the main culprit.
Methods: We evaluated the presence of large & small (autonomic) fiber PN in 54 consecutive patients with PD or
parkinsonism in a tertiary outpatient clinic from Brazil. Initial PN screening consisted of history/neurological exam
and skin wrinkling test (SWT). In addition, we also performed Nerve conduction studies/Electromyography (NCS/EMG)
in all patients with PN signs/symptoms and/or abnormal SWT.
Results: Thirty eight patients with PD (10 women, mean age: 63 ± 2.1 years, P < 0.05 versus parkinsonism, mean disease
duration: 8 ± 0.8 years) and 16 patients with other forms of parkinsonism [7 women, mean age: 50.1 ± 3.9 years, mean
disease duration: 6.9 ± 1.1 years] completed clinical neuromuscular evaluation. SWT was performed in 48 patients
(33 PD, 15 parkinsonism). In the PD group, SWT was abnormal in 57.6 % of the tested patients (comprising 50 %
of all PD patients). In the parkinsonism group, SWT was abnormal in 37.5 % (comprising 35.3 % of all parkinsonism
patients). NCS/EMG was performed in 39 patients (26 PD and 13 parkinsonism). Twelve out of the 26 PD (34.2 % of
all PD) and 4 out of the 13 parkinsonism (23.5 % of all parkinsonism) had abnormal NCS/EMG results. Neuropathy
prevalence was similar in PD and parkinsonism groups as detected either by NCS/EMG or SWT.
Conclusions: Large fiber and small (autonomic) fiber PN are common in patients with PD and parkinsonism.
The etiology for the neuropathy was likely to be multifactorial and may be secondary to PD itself.
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conduction studies; PD, Parkinson’s disease; PN, Peripheral neuropathy; SFN, Small fiber neuropathy; SNAP, Sensory nerve
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Background
Although autonomic involvement was extensively des-
cribed in Parkinson’s disease (PD) and other forms of
parkinsonism (e.g. multiple system atrophy, Lewy body
disease), the presence of sensorimotor peripheral neuro-
pathy (PN) was only detailed in case reports and small
case series until recently [1, 2]. In the early 2000s,
peripheral neuropathy was thought to be present in gen-
etic forms of Parkinson’s disease [3, 4]. In 2008, Toth et
al were among the first to report that a significant per-
centage of patients with PD were affected by peripheral
neuropathy [5]. Toth et al. reported symptomatic neuro-
pathy in 9.8 % of 500 PD patients, and attributed that to
high homocysteine levels due to levodopa use (levodopa
effect on vitamin B12 metabolism) [5]. The same group
also subsequently reported higher neuropathy prevalence
(about 6x greater than controls) in a case-control study
of PD patients [6]. Neuropathy was axonal, more
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prevalent in older patients with high homocysteine/
methylmalonic acid levels and higher Unified Parkinson’s
disease rating scale (UPDRS) scores. A multicenter study
in Italy also reported prevalence of 19.4 % of neuropathy
in PD patients, due to long term levodopa exposure,
older age and high homocysteine/methylmalonic acid
and low vitamin B12 levels [7].
In 2005, we started a study to screen neuropathy in
Brazilian patients with PD. Although full neuropathy
screening could not be initially completed due to financial
constraints, we reported preliminary findings of 10 symp-
tomatic PD patients with neuropathy [8]. In our study,
neuropathy phenotype was diverse and included demyelin-
ating neuropathies. Co-morbidities were also different from
previous studies and included monoclonal gammopathy of
uncertain significance and hypothyroidism [8]. Recently,
additional observations have broadened the clinical
spectrum of peripheral neuropathies in PD patients to in-
clude demyelinating and small fiber neuropathies [9–11].
Here, we describe the results of a study aimed to screen
large and small (autonomic) fiber neuropathy in patients
with PD and parkinsonism. Screening for small (autonomic)
fiber neuropathy was done by skin wrinkling test, an inex-
pensive bedside diagnostic tool that was recently considered
to be comparable to skin biopsy testing. Part of this study
has been reported in abstract form elsewhere [12].
Methods
Subjects
All consecutive patients with the diagnosis of Parkinson’s
disease or parkinsonism (secondary to Willson disease
N = 4, progressive supranuclear palsy/corticobasal de-
generation N = 3, multiple system atrophy N = 3, Lewy
body disease N = 1, vascular parkinsonism N = 1 and un-
established etiology N = 4) seen at a newly established ter-
tiary outpatient clinic at the Federal University of Ceará
were offered to participate in this study. Patients were en-
rolled over a period of 1 year and one additional year was
necessary to complete the diagnostic testing and labora-
tory work-up. Very few patients declined to participate in
the study (the authors estimate that less than 10 % of the
eligible patients) and no patient withdrew from the study
after initial enrollment.
Techniques and experimental design
The study consisted in a standard evaluation for the
presence of large and small (autonomic) fiber peripheral
neuropathy. Fifty-four patients were enrolled in approxi-
mately 1 year and completed the neuromuscular evalu-
ation. A board-certified neurologist (by both the American
Academy of Neurology and Academia Brasileira de
Neurologia) conducted the initial PN screening. It con-
sisted of history gathering (e.g. complaints of paresthesias,
burning feet, unexplained worsening gait) and detailed
neurological exam looking for classicial findings of neuro-
pathy (predominantly distal atrophy, decreased or ab-
sent deep tendon reflexes, length-dependent sensory
loss). Thereafter, a group of medical students super-
vised by the corresponding author conducted the skin
wrinkling test (SWT), according to the same protocol
described by Teoh et al [13] that we had also previously
employed [14]. Briefly, the SWT consisted of hand
immersion in NaCl at 0.5 mmol/l at 40.5oC during
30 min. Thereafter, skin wrinkling was visually graded
in 4 digits (all but the thumb) and a mean score of
wrinkling was created. Patients were considered to have
neuropathy if mean SWT score was lower than 2. If a
patient had signs or symptoms of peripheral neur-
opathy and/or an abnormal SWT, this initial evaluation
was followed by a nerve conduction study/electromyog-
raphy (NCS/EMG). The final result of the neuromuscu-
lar evaluation was based on the combined results of the
neurological exam, SWT and NCS/EMG. For the lower
extremities, the following cut-offs were used to diagnose
abnormalities in the nerve conduction studies: peroneal
compound muscle action potential (CMAP) amplitudes
(2.5 mV), tibial CMAP amplitudes (3.5 mV), sural sensory
nerve action potential (SNAP) amplitudes (4 uV) and
tibial, peroneal and sural nerve conduction velocities
(39 m/s). Absent sural responses were not considered to
be necessarily abnormal in patients older than 60 years.
The medical charts of all patients were also reviewed, in-
cluding the risk factors for neuropathy. Basic laboratory
tests were requested to pursue the work-up for neuropathy
and/or clinical evaluation for the presence of thyroid dis-
eases, diabetes mellitus (DM) or vitamin B12 deficiency.
Although most of the patients routinely had prior evalu-
ation for diabetes and thyroid disease by primary care phy-
sicians (although not all test results were available),
screening for B12 deficiency could only be documented in
63.2 % of the PD and 56.3 % of the parkinsonism group.
Statistics and ethics
This study was approved by the local Institutional Review
Board of the Universidade Federal do Ceará (Comitê de
Ética em Pesquisa do Hospital Universitário Walter
Cantídio). All patients signed an informed consent
prior to the enrollment in this study. Descriptive statis-
tics followed by Chi-square and Fischer exact test and
parametric (t test) and non-parametric tests (Mann-
Whitney test) were then performed (choice according
to Gaussian or non-Gaussian distribution). Thereafter,
univariate regression analysis was performed to establish
whether each variable was a risk factor for neuropathy.
One-Way ANOVA followed by the Holm-Sidak test was
used to compare the results of the electrodiagnostic tests.
Results are detailed as mean ± SEM and differences were
considered significant if P < 0.05.
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Results
Clinical and demographic features
Table 1 compares the demographic characteristics of the
38 patients with PD and 16 patients with other forms of
parkinsonism that completed our work-up. Patients with
PD were older than patients with parkinsonism (P < 0.05,
Mann Whitney test). However, age of onset, disease dur-
ation and gender distribution were similar in both groups,
despite a trend for higher percentage of women in the par-
kinsonism group and for older age of onset and longer
disease course in the PD group. Mean Hoehn and Yahr
scores in the PD group were 2.6 ± 0.1 (score of 2 indicates
bilateral involvement with preservation of balance, while
score of 3 means bilateral involvement with mild-moderate
impairment of postural reflexes). Most of the PD patients
were treated with levodopa and 68.8 % of the parkinsonism
group were taking levodopa. A third of the PD patients
and 31 % of the parkinsonism group were treated with pra-
mipexol while 38.9 % of the PD and none from the parkin-
sonism group were treated with amantadine and only 8.3
and 18.8 (respectively) were treated with biperiden.
Results of small (autonomic) fiber neuropathy assessment
Skin Wrinkling Test (SWT) was performed in 49 patients,
33 with PD and 15 with other forms of parkinsonism. No
statistical difference was observed in the percentage of
patients with abnormal SWT between the 2 groups: 19
out of 33 of the PD group (57.6 %, mean SWT grade:
1.98 ± 0.2) and 6 out of 15 of the patients with parkin-
sonism (40 %, mean SWT grade: 2.3 ± 0.3). Among the
patients with evidence of small (autonomic) fiber neur-
opathy in the PD group, 10 % had diabetes, 5 % thyroid
disease, 5 % B12 deficiency and 5 % had been treated
for leprosy in the past while additional 15 % had B12
levels <300. Among the patients with evidence of small
fiber neuropathy in the parkinsonism group, 12.5 % had
diabetes mellitus. Therefore, in 65 % of the PD patients
and among 87.5 % of the patients with parkinsonism, no
common etiology of peripheral neuropathy was identified.
Results of large fiber neuropathy assessment
NCS/EMG was performed in 39 patients (26 PD and
13 with other forms of parkinsonism). 12 out of the
26 PD (34.2 % of all PD) and 4 out of the 13 from
the parkinsonism group (23.5 % of all patients from
the parkinsonism group) had abnormal NCS/EMG results.
As expected, patients with abnormalities suggestive of
peripheral neuropathy on the screening neurological exam
were more likely to have abnormal EMG (P = 0.04, Fischer
exact test). Neuropathy prevalence was similar in the
groups with PD and parkinsonism (P > 0.05), whether PN
was assessed by SWT, NCS/EMG or clinically (final com-
bined neuromuscular evaluation).
Table 1 displays the results of the most important
neurophysiological parameters from the lower extremities
nerve conduction studies in patients with PD and other
forms of parkinsonism. No statistically significant differ-
ence was evidenced between PD and other forms of par-
kinsonism for the tibial and peroneal motor amplitudes
and conduction velocities as well as from sural sensory
amplitudes and conduction velocities. Figures 1 and 2 fur-
ther detail the electrodiagnostic findings in patients with
PD and parkinsonism with and without large and small
fiber neuropathy. As can be seen in Fig. 1a, patients with
large-fiber neuropathy and PD had lower peroneal CMAP
amplitudes than patients without large-fiber neuropathy
(P < 0.01). Figures 1a and 2a also reveal that despite a
trend for lower sural SNAP amplitudes in patients with
PD and large-fiber neuropathy, there was no statistically
significant difference in sural SNAP amplitudes in patients
with PD or parkinsonism with and without large-fiber
neuropathy. Also, as can be seen in Figs. 1b and 2b,
peroneal and sural conduction velocities in patients
with PD or parkinsonism were not significantly different
in patients with small or large-fiber neuropathy.
Risk factor assessment for large and small (autonomic)
fiber neuropathy
Patients with EMG abnormalities were older: 65.5 ± 3.8
vs. 53 ± 3 years (P = 0.01, Mann-Whitney test), but ab-
normalities on SWT scores were not associated with age.
Table 1 Demographic characteristics and risk factors for





Age 63 ± 2.1 50.1 ± 3.9*
% Female 26.3 43.8
Age of onset (years) 54.3 ± 2 42.1 ± 4.3
Disease duration (years) 8 ± 0.8 6.9 ± 1.1
Definite and Possible Risk Factors for Neuropathy
% Diabetes mellitus 10.5 25
% Thyroid disease 6.6 0
% B12 level <200 13 22.2
% B12 level <300 20.8 44.4
% Levodopa use 97.2 68.8
Neurophysiological studies
Peroneal CMAP (mV) 3.99 ± 0.47 3.8 ± 0.66
Peroneal CV (m/s) 46.9 ± 1.02 49.3 ± 1.56
SNAP (μV) 11.9 ± 1.16 14.5 ± 3.77
Sural CV (m/s) 48.9 ± 0.88 46.3 ± 1.12
Tibial CMAP (mV) 8.67 ± 0.88 9.8 ± 1.3
Tibial CV (m/s) 47 ± 0.76 46.2 ± 1
*P < 0.05, Student t test
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In addition, patients with either SWT or EMG abnor-
malities were not more likely to be older than normal
patients. Patients with EMG abnormalities were more
likely to be older at the disease onset (57.2 ± 3.8 versus
45.3 ± 3.1 years, P = 0.01) but there was no significant
relationship between EMG abnormalities and disease
duration. In addition, there wasn’t any significant rela-
tionship between the age of disease onset or disease dur-
ation and SWT scores (P = 0.44).
Univariate regression analysis showed a significant cor-
relation between age and EMG abnormalities (P = 0.01)
but not with SWT scores (P = 0.53). Univariate regres-
sion analysis also showed a significant correlation be-
tween age of onset and EMG abnormalities (P = 0.03).
Patients with higher Hoehn and Yahr stage scores were
more likely to have EMG abnormalities (Fischer exact
test, P = 0.02) than patients with lower scores, but no
significant difference was found between SWT and
Hoehn and Yahr stage scores. Patients taking biperiden
were more likely to have EMG abnormalities (P = 0.05,
Fischer’s exact test). Patients with neuropathy were not
more likely to have diabetes mellitus, hypothyroidism,
B12 deficiency, use levodopa, pramipexole or amanta-
dine. Almost all patients from the PD group were taking
levodopa but patients with PD were more likely to take
levodopa than patients with parkinsonism (P = 0.003).
However, the total amount of levodopa exposure on
each patient was not quantified, and therefore, the cu-
mulative effect of levodopa on the neuropathy develop-
ment could not be assessed.
Regression analysis of tibial and peroneal CMAP am-
plitudes and conduction velocities or sural SNAP and
conduction velocities versus the presence of DM or B12
levels was not significant. In addition, regression analysis
also did not disclose any significant relationship between
SWT scores and electrodiagnostic parameters, i.e. tibial
and peroneal CMAP amplitudes and conduction veloci-
ties or between sural SNAP and conduction velocities.
Discussion
Our study revealed that large fiber and small (autonomic)
fiber PN are common in patients with PD and other forms
Fig. 1 Part a shows mean peroneal compound motor action potential (CMAP, in mV) amplitudes and mean sural sensory nerve action potential
(SNAP, in μV) amplitudes in patients with Parkinson’s disease (PD). “PD all patients” refers to mean values from the whole group (all patients with PD),
“PD no PN” refers to mean values from PD patients without large fiber neuropathy, “PD SFN” refers to patients with PD and small fiber neuropathy and
“PD Neuropathy” to mean values in patients with PD and large-fiber neuropathy. Part b shows mean values of peroneal motor and sural sensory
conduction velocities in the same groups
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of parkinsonism. Those findings are consistent with
several prior studies that demonstrated that large fiber
neuropathy is highly prevalent in PD patients [6–9]. A
recent review evaluated all published studies about this
topic [15].
However, to our knowledge, this is the first study to
compare the prevalence of neuropathy in patients with PD
and parkinsonism and where a systematic screening for
small (autonomic) fiber neuropathy (clinical and with skin
wrinkling test) was conducted in both groups (patients
with PD and other forms of parkinsonism). We observed
that 57.6 % of the PD group (50 % of all PD) and 37.5 % of
the patients with parkinsonism (35.3 % of all patients from
the parkinsonism group) who underwent SWT had an ab-
normal SWT result. These findings are consistent with
several recent studies that attempted to evaluate the in-
volvement of the small fibers in patients with PD. Nolano
et al. were the first to report significant reduction of
epidermal nerve fibers in 100 % of the PD patients [16].
Wang et al. have described deposits of α-synuclein in
autonomic but not in sensory nerve fibers in 100 % of the
PD patients [11]. Higher α-synuclein ratios correlated with
autonomic dysfunction and Hoehn and Yahr scores [11].
Donadio et al. have also reported anti-phosphorylated α-
synuclein deposits in 100 % of the distal and proximal skin
from PD patients [12].
One of the limitations of our small fiber neuropathy
assessment is that we only employed SWT. We were
not able to run a complete battery of autonomic tests,
questionnaires for evaluation of autonomic dysfunction
(e.g. COMPASS) or additional tests to evaluate sensory
C fibers, such as skin biopsies. Skin wrinkling test (SWT)
is an unexpensive and easy tool to detect abnormalities in
small fiber function. SWT has been increasingly employed
for small fiber evaluation and has demonstrated to be as
accurate as skin biopsies for the diagnosis of small fiber
Fig. 2 Part a shows mean peroneal compound motor action potential (CMAP, in mV) amplitudes and mean sural sensory nerve action potential
(SNAP, in μV) amplitudes in patients with parkinsonism. “Parkinsonism all patients” refers to mean values from the whole group (all patients with
parkinsonism), “Parkinsonism no PN” refers to mean values from parkinsonism patients without large fiber neuropathy, “Parkinsonism SFN” refers
to patients with parkinsonism and small fiber neuropathy and “Parkinsonism Neuropathy” to mean values in patients with Parkinsonism and
large-fiber neuropathy. Part b shows mean values of peroneal motor and sural sensory conduction velocities in the same groups
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neuropathy [13]. However, SWT more accurately evaluate
the function of autonomic fibers and therefore not neces-
sarily somatic small fibers. Among 65 % of the PD patients
with small fiber neuropathy, no common etiology of per-
ipheral neuropathy was identified. Exposure to levodopa
was not a risk factor per se although we have not quanti-
fied the extent of levodopa exposure nor correlated the
total exposure with the development of small fiber neuro-
pathy. It is also important to emphasize that even when a
possible etiology was identified, this abnormality cannot
be necessarily attributed as the cause of neuropathy, since
it may be a contributory and not the etiological factor.
Large-fiber neuropathy was not as prevalent as small
fiber neuropathy in patients with either PD or parkinsonism
due to other causes. As expected, they were more likely to
have abnormalities suggestive of peripheral neuropathy on
the neurological exam (P = 0.04). Patients with large-fiber
neuropathy and PD had lower peroneal CMAP amplitudes
than patients without large-fiber neuropathy (P < 0.01), but
despite a trend for lower sural SNAP amplitudes in pa-
tients with PD and large-fiber neuropathy, sural SNAP
amplitudes were not significantly different (Fig. 1a).
This may be explained by the fact that patients with
small fiber neuropathy may have earlier signs of sensory
axonal involvement, therefore dropping the amplitudes
of sural SNAP amplitudes and preventing them to
reach the level of statistical significance. Peroneal
(motor) and sural (sensory) conduction velocities were
also not statistically different, reinforcing the presence
of an axonal phenotype (no patient from the PD or par-
kinsonism group had demyelinating neuropathy). In
most studies of neuropathy and PD, the sensorimotor
axonal phenotype is predominant [5, 7, 15].
Although both large and small fiber neuropathy were
highly prevalent in PD and parkinsonism patients, there
was no correlation between SWT scores and electrodiag-
nostic parameters diagnostic of large-fiber neuropathy.
In addition, patients with EMG abnormalities were older
and had higher Hoehn and Yahr stage scores while ab-
normalities on SWT scores were not associated with age.
Patients with EMG abnormalities (but not with SWT ab-
normalities) were more likely to be older at the disease
onset but EMG abnormalities were not dependent on
disease duration. Overall those findings suggest that small
(autonomic) and large-fiber neuropathy have different
profiles, with early small fiber involvement more linked to
PD itself while large-fiber involvement may be secondary
to a mixture of progression of small fiber disease related
to age, disease severity, co-morbidities (such as diabetes
and hypothyroidism) and possibly levodopa exposure. The
contribution of the different comorbidities rather than
true neuropathy determinants is further reinforced by the
lack of correlation between tibial and peroneal CMAP
amplitudes, conduction velocities or sural SNAP and
conduction velocities versus the presence of DM or B12
as detected by regression analysis. It is also important to
emphasize that we did not test for more controversial, but
possible contributory factors, such as pyridoxine defi-
ciency and it would useful to know the exact percentage
of patients with large and small-fiber neuropathy detected
by our screening tools in an age-matched population in
the same institution.
Conclusions
In summary, large fiber and small (autonomic) fiber
peripheral neuropathies are common in patients with
PD and parkinsonism. Neuropathy etiology seems to be
multifactorial in PD patients, but possibly secondary to
PD itself (especially small fiber involvement). Long-term
follow-up of patients with the different contributory
factors and evaluation of patients with early stage of PD
will be important to further answer additional questions
about the etiology of PN in patients with PD.
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